WallStreetZenWallStreetZen

NYSEMKT: PTHS
Pelthos Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PTHS

Based on 6 analysts offering 12 month price targets for Pelthos Therapeutics Inc

Min Forecast
$48.00+76.67%
Avg Forecast
$54.83+101.81%
Max Forecast
$66.00+142.91%

Should I buy or sell PTHS stock?

Based on 6 analysts offering ratings for Pelthos Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PTHS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PTHS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PTHS stock forecasts and price targets.

PTHS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-04-01
lockedlocked$00.00+00.00%2026-03-19
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-02-26
Lake Street
Bottom 23%
23
Strong BuyInitiates Coverage On$50.00+84.03%2025-12-03

1 of 1

Forecast return on equity

Is PTHS forecast to generate an efficient return?

Company
155.74%
Industry
85.08%
Market
169.03%
PTHS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PTHS forecast to generate an efficient return on assets?

Company
37.6%
Industry
29.31%
PTHS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PTHS earnings per share forecast

What is PTHS's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$9.19
Avg 2 year Forecast
-$1.69
Avg 3 year Forecast
$5.24

PTHS revenue forecast

What is PTHS's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$62.0M+123.97%
Avg 2 year Forecast
$113.3M+308.9%
Avg 3 year Forecast
$170.4M+514.96%
PTHS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PTHS revenue growth forecast

How is PTHS forecast to perform vs Biotechnology companies and vs the US market?

Company
82.82%
Industry
35.58%
Market
13.82%
PTHS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PTHS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PTHS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PTHS$27.17$54.83+101.81%Strong Buy
ICCC$10.50N/AN/A
PMN$10.36$26.50+155.79%Strong Buy
ONCY$0.81$10.00+1,134.57%Buy
AARD$4.20$13.14+212.93%Buy
View Top Biotech Stocks

Pelthos Therapeutics Stock Forecast FAQ

Is Pelthos Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NYSEMKT: PTHS) stock is to Strong Buy PTHS stock.

Out of 6 analysts, 4 (66.67%) are recommending PTHS as a Strong Buy, 2 (33.33%) are recommending PTHS as a Buy, 0 (0%) are recommending PTHS as a Hold, 0 (0%) are recommending PTHS as a Sell, and 0 (0%) are recommending PTHS as a Strong Sell.

If you're new to stock investing, here's how to buy Pelthos Therapeutics stock.

What is PTHS's earnings growth forecast for 2026-2028?

(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.49%.

Pelthos Therapeutics's earnings in 2026 is -$51,588,939.On average, 9 Wall Street analysts forecast PTHS's earnings for 2026 to be -$31,924,147, with the lowest PTHS earnings forecast at -$45,233,434, and the highest PTHS earnings forecast at -$11,568,684. On average, 9 Wall Street analysts forecast PTHS's earnings for 2027 to be -$5,867,236, with the lowest PTHS earnings forecast at -$9,469,047, and the highest PTHS earnings forecast at $547,414.

In 2028, PTHS is forecast to generate $18,222,112 in earnings, with the lowest earnings forecast at $5,041,076 and the highest earnings forecast at $39,632,780.

What is PTHS's revenue growth forecast for 2026-2028?

(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual revenue growth rate of 82.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.82%.

Pelthos Therapeutics's revenue in 2026 is $27,701,000.On average, 9 Wall Street analysts forecast PTHS's revenue for 2026 to be $215,639,443, with the lowest PTHS revenue forecast at $192,206,644, and the highest PTHS revenue forecast at $235,134,336. On average, 9 Wall Street analysts forecast PTHS's revenue for 2027 to be $393,686,309, with the lowest PTHS revenue forecast at $345,374,844, and the highest PTHS revenue forecast at $437,931,270.

In 2028, PTHS is forecast to generate $592,076,126 in revenue, with the lowest revenue forecast at $505,706,348 and the highest revenue forecast at $721,509,146.

What is PTHS's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: PTHS) forecast ROA is 37.6%, which is higher than the forecast US Biotechnology industry average of 29.31%.

What is PTHS's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PTHS price target, the average PTHS price target is $54.83, with the highest PTHS stock price forecast at $66.00 and the lowest PTHS stock price forecast at $48.00.

On average, Wall Street analysts predict that Pelthos Therapeutics's share price could reach $54.83 by May 15, 2027. The average Pelthos Therapeutics stock price prediction forecasts a potential upside of 101.81% from the current PTHS share price of $27.17.

What is PTHS's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: PTHS) Pelthos Therapeutics's current Earnings Per Share (EPS) is -$21.85. On average, analysts forecast that PTHS's EPS will be -$9.19 for 2026, with the lowest EPS forecast at -$13.01, and the highest EPS forecast at -$3.33. On average, analysts forecast that PTHS's EPS will be -$1.69 for 2027, with the lowest EPS forecast at -$2.72, and the highest EPS forecast at $0.16. In 2028, PTHS's EPS is forecast to hit $5.24 (min: $1.45, max: $11.40).

What is PTHS's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: PTHS) forecast ROE is 155.74%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.